Long Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy
June 08 2017 - 7:00AM
Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the
“Company”) today announced the publication of long-term follow-up
data reporting patient satisfaction and surveillance for cancer
recurrences following use of Cytori Cell Therapy™ for breast
reconstruction following partial mastectomy and radiation for
breast cancer treatment.
This Cytori-supported, investigator-initiated
study, which was peer-reviewed and published in June 2017 edition
of Surgery Today, followed ten patients treated with a single
therapeutic administration of Cytori Cell Therapy at Kyushu
University. None of the ten patients experienced cancer recurrence
or new cancer formation through a median of 8.5 years of follow up
(range 5.1-8.9 years; mean 7.8±1.5 years).
Scarring and tissue volume loss, particularly following extirpative
surgery and adjuvant radiation therapy remains a significant
reconstructive problem for survivors of breast cancer. Cytori’s
technology is available to doctors in Japan under the new
regenerative medicine regulations for reconstructive purposes.
Several pre-clinical and clinical studies suggest that Cytori Cell
Therapy has potential to help alter markers and outcomes related to
fibrosis characterized by tissue fibrosis (scar), irrespective of
the etiology of the fibrosis.
Currently, there are three ongoing clinical trials
involving Cytori Cell Therapy in which fibrosis is an important
pathophysiologic feature of the primary disease: (1) Cytori’s Phase
III STAR trial for hand manifestations of systemic scleroderma, (2)
the investigator-initiated ADRESU trial in Japan for
post-prostatectomy urinary incontinence and (3) Cytori’s RELIEF
trial for thermal burns. The published report can be found at the
following link: Ito et al, Surg Today (2017) DOI
10.1007/s00595-017-1544-4.
About Cytori
Therapeutics, Inc.
Cytori is a therapeutics company developing
regenerative and oncologic therapies from its proprietary cell
therapy and nanoparticle platforms for a variety of medical
conditions. Data from preclinical studies and clinical trials
suggest that Cytori Cell Therapy™ acts principally by improving
blood flow, modulating the immune system, and facilitating wound
repair. As a result, Cytori Cell Therapy™ may provide benefits
across multiple disease states and can be made available to the
physician and patient at the point-of-care through Cytori’s
proprietary technologies and products. Cytori Nanomedicine™ is
developing encapsulated therapies for regenerative medicine and
oncologic indications. For more information, visit
www.cytori.com.
Cautionary Statement Regarding
Forward-Looking Statements
This press release includes forward-looking
statements regarding events, trends and business prospects, which
may affect our future operating results and financial position.
Such statements, including, but not limited to, statements
regarding potential benefits of Cytori Cell Therapy™ are subject to
risks and uncertainties that could cause our actual results and
financial position to differ materially. Some of these risks and
uncertainties include: risks in the conduct of Cytori-conducted and
investigator-conducted clinical trials; risks in the collection and
results of clinical data; risks associated with final clinical
outcomes; regulatory risks and uncertainties; risks related to
dependence on third party performance; and other risks and
uncertainties described under the "Risk Factors" section in
Cytori's Securities and Exchange Commission Filings on Form 10-K
and Form 10-Q. Cytori assumes no responsibility to update or revise
any forward-looking statements contained in this press release to
reflect events, trends or circumstances after the date of this
communication.
Cytori Therapeutics, Inc.
Tiago Girao, 1.858.458.0900
ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Apr 2023 to Apr 2024